[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Medicine Greifswald\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":303},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,83,107,130,151,191,216,246,273],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100626897","efficacy-of-the-proactive-automatized-lifestyle-intervention-100626897",false,"NCT07441603","Efficacy of the Proactive Automatized Lifestyle Intervention","Investigating the Efficacy of the Proactive Automatized Lifestyle Intervention Among General Hospital Patients","ePAL","Inclusion Criteria:\n\n* Admitted to participating wards of the University Medicine Hospital Greifswald on Mondays through Thursdays\n\nExclusion Criteria:\n\n* cognitively or physically incapable\n* presence of a highly infectious disease\n* discharged or transferred within the first 24 hours\n* already recruited for study during previous stay\n* insufficient German language skills\n* employed the conducting research department\n* accompanying persons\n* no email address (and no phone number)","ALL","18 Years","64 Years",{"count":21,"type":22},788,"ESTIMATED","INTERVENTIONAL",[25],"NA","Background: Individual brief behavior change interventions often do not sufficiently address the common co-occurrence of multiple health risk behaviors among people. In addition, many interventions often fail to reach the majority of the target population and particularly those people who need them the most. To address these core challenges of individual prevention research, the \"Proactive Automatised Lifestyle intervention (PAL)\" was developed, a proactive screening and brief intervention driven by psychological health behavior change theory to motivate participants for behavior change. The trial ePAL aims to investigate the efficacy of the multi-behavior change intervention adressing tobacco smoking, alcohol use, diet and physical activity among general hospital patients over 2 years; and to investigate differential efficacy in different subgroups of patients.\n\nMethods: All patients admitted to non-intensive care wards on five medical departments within the University Medicine Hospital Greifswald (internal medicine A \\& B, surgery, trauma surgery, ear-nose-throat) and aged 18 to 64 years are systematically approached by study assistants and asked to first participate in a survey and then in the randomizd controlled trial, irrespective of their reason of admission. A total of 788 participants is allocated to two study groups. The intervention group receives individualized feedback on all four health risk behaviors to enhance motivation to change identified health risk behaviors. The feedback is driven by psychological behavior change theory, tailored to the participants' current stages of change and delivered after baseline and at months 1 and 3. The control group receives routine care and minimal assessment only. Follow-ups are conducted at months 6, 12 and 24 after baseline; and more are planned for. Efficacy will be measured concerning self-reported change in health risk behaviors, health and motivation to change measures using latent growth curve modelling.\n\nDiscussion: The trial will provide information on the efficacy of a population-based and individually tailored brief intervention to systematically provide individualized feedback to each patient for a healthy living. When found to be effective and implemented widely, such interventions may contribute to the prevention of widespread non-communicable diseases.",[28,29,30,31,32,33,34],"Health Risk Behaviors","Tobacco Smoking","Alcohol Use","Unhealthy Diet, Exercise, Smoking, and Alcohol Use","Unhealthy Diet","Insufficient Physical Activity","Vegetable Intake","RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":39},"2026-06-25",{"date":43,"type":22},"2029-06",{"name":45,"class":46},"University Medicine Greifswald","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":47},"100622414","autophagy-enhancers-to-reduce-sleep-disturbances-100622414","NCT07383311","Autophagy-Enhancers to Reduce Sleep Disturbances","Autophagy-Enhancers to Reduce Sleep Disturbances: A Combined Approach","SpSleep","Inclusion Criteria (SCD participants):\n\n* Men and women\n* Written consent to participate in the study\n* German at native speaker level\n* Age between 55 and 70 years\n* Subjective Cognitive Decline operationalized as:\n\n  1. Subjectively reported decline in cognitive function (particularly memory) despite objectively normal cognitive performance (e.g., WMS-LM)\n  2. Preservation of functional independence\n  3. No dementia\n\nInclusion Criteria (MCI patients):\n\n* Men and women\n* Written consent to participate in the study\n* German at native speaker level\n* Age between 55 and 70 years\n* Mild cognitive impairment (MCI) operationalized as:\n\n  1. A change in cognitive abilities reported by the patient, relatives or clinic staff (i.e. historical or observed evidence of deterioration over time)\n  2. Objective evidence of memory impairment (at least 1.0 Standard Deviation (SD) below the normal range on the Wechsler Logical Memory Scale (WMS-LM)); other cognitive domains may also be affected (i.e. amnestic MCI and amnestic + MCI)\n  3. Preservation of independence of functional abilities\n  4. No dementia\n\nExclusion Criteria (SCD and MCI participants):\n\n* Patients who are unable to give informed consent\n* Polyamine intake via dietary supplements and\u002For participation in corresponding intervention studies\n* Dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)\n* Any condition that impairs clinical or neuropsychological examination procedures\n* Diabetes mellitus\n* Polycystic ovary syndrome\n* Signs of epilepsy, focal brain lesion or head injury with loss of consciousness or immediate post-injury confusion\n* Previous stroke\n* Severe untreated medical problems or unstable medical condition\n* Current major depressive episode\n* Psychotic disorder\n* Bipolar disorder\n* Current or previous substance abuse\n* Other neurodegenerative disease, e.g. Parkinson's disease\n* Vascular dementia\n* Alcohol abuse\n* Participation in an interventional study in the last 3 months and during the entire study period\n* Sleep disorders\n* Taking medication that primarily affects the central nervous system (e.g. antipsychotics, antidepressants, benzodiazepines or any type of over-the-counter sleep-inducing medication such as valerian; anti-dementia medication)\n* Known intolerances or allergies to wheat germ, gluten or histamine\n\nInclusion criteria (healthy controls):\n\n* Men and women\n* Written consent to participate in the study\n* German at native speaker level\n* Age between 55 and 70 years\n* Subjective cognitive disorders are denied\n\nExclusion criteria (healthy controls):\n\n* Subjects who are not able to give informed consent\n* Polyamine intake via dietary supplements and\u002For participation in corresponding intervention studies\n* Dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)\n* Mild cognitive impairment (MCI), defined as described above in the patient inclusion criteria\n* Any condition that interferes with clinical or neuropsychological examination procedures\n* Diabetes mellitus\n* Polycystic ovary syndrome\n* Signs of epilepsy, focal brain lesion or head injury with loss of consciousness or immediate post-injury confusion\n* Previous stroke\n* Severe untreated medical problems or unstable medical condition\n* Current major depressive episode\n* Psychotic disorder\n* Bipolar disorder\n* Current or past substance abuse\n* Other neurodegenerative disease, e.g. Parkinson's disease\n* Vascular dementia\n* Alcohol abuse\n* Participation in an interventional study in the last 3 months and during the entire study period\n* Sleep disorders\n* Taking medication that primarily affects the central nervous system (e.g. antipsychotics, antidepressants, benzodiazepines or any type of over-the-counter sleep-inducing medication such as valerian; anti-dementia medication)",true,"55 Years","70 Years",{"count":60,"type":22},76,[25],"This clinical trial investigates the effects of spermidine supplementation on sleep quality and sleep-dependent memory consolidation in older adults with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), two populations at increased risk of future cognitive decline and dementia. Impaired sleep has been identified as a modifiable factor contributing to cognitive decline, and interventions targeting sleep architecture could offer therapeutic potential to prevent or slow down this decline.\n\nSpermidine is a naturally occurring polyamine found in foods such as wheat germ and soybeans. It induces autophagy, a cellular degradation and recycling process essential for neuronal maintenance and function. In animal studies, spermidine has been shown to improve memory performance, reduce neuroinflammation, and support mitochondrial health. Preliminary findings from human trials in individuals with SCD or MCI suggest potential cognitive benefits of spermidine, but results are not unequivocal, and the impact on sleep has not been systematically evaluated.\n\nIn this randomized, double-blind, placebo-controlled trial, 76 participants aged 55 to 70 years with SCD or MCI will receive either spermidine (6 mg\u002Fday) or a placebo for 12 weeks. Sleep will be evaluated using overnight EEG in a controlled laboratory setting, focusing on measures such as slow-wave sleep and sleep spindle activity. Memory performance will be assessed before and after the intervention using standardized neuropsychological testing. Numerical skills will be tested at baseline only to compare SCD and MCI participants with healthy controls.\n\nBlood samples will be collected to quantify metabolic indicators, neurodegeneration-related biomarkers, and autophagy-associated proteins. A control group of 38 cognitively healthy individuals will undergo comparable sleep and cognitive assessments without receiving any supplementation.\n\nThe primary objective of the study is to characterize the impact of spermidine on sleep-dependent memory consolidation and to identify associated biological changes relevant to aging and neurodegeneration. The results may inform the development of non-pharmacological strategies aimed at preserving cognitive function in individuals at risk for dementia.",[64,65],"Mild Cognitive Impairment Due to Alzheimer's Disease","Subjective Cognitive Decline (SCD)",[67,68,69,70,71,72,73,74,75],"Mild Cognitive Impairment","Autophagy","sleep","Spermidine","memory consolidation","electroencephalography","polysomnography","randomized controlled trial","subjective cognitive decline","2026-06-29",{"date":38,"type":39},{"date":79,"type":39},"2025-10-28",{"date":81,"type":22},"2029-05",{"name":45,"class":46},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":56,"sex":17,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100644257","acupuncture-mechanism-in-relief-of-gag-reflex-100644257","NCT07664826","Acupuncture Mechanism in Relief of Gag Reflex","The Mechanism of Acupuncture for Relief of Pharyngeal (Gag) Reflex - an Experimental Crossover Investigation","AcuGagDiff","Inclusion Criteria:\n\n1. Healthy volunteers aged between 20-40 years old with an American Society of Anesthesiologists physical status of I to II naïve to acupuncture\n2. Participants without previous opioid and psychotropic medication\n3. Without use of recreational drugs 3 days prior to study sessions\n4. Without systemic disease or local skin lesions at the sites of acupuncture\n5. Without drug allergy to local anesthetics, especially EMLA preparation\n6. Participants who have given written informed consent\n\nExclusion Criteria:\n\n1. Local skin infection at the sites of acupuncture\n2. Aged \\\u003C 20 or \\> 35 years\n3. History of drug allergy to local anesthetics\n4. Participants who are unable to understand the consent form or to use numeric rating scale NRS-11\n\nDiscontinuation Criteria\n\n1. Any adverse effects during study session\n2. In case of local or systemic infection\n3. In case if subject will withdraw from participation in this study at any time, for any reason, specified or non-specified, and without penalty or loss of benefits","20 Years","40 Years",{"count":94,"type":22},30,[25],"The gag reflex relief effect of acupuncture of CV24 acupoint will be compared to acupuncture of PC6 and K3 acupoints in healthy volunteers in crossover mode. Second step will be the investigation whether local anesthesia using EMLA creme will block the gag relief effect of CV24 acupuncture in healthy volunteers.",[98],"Gag (Pharyngeal) Reflex","2026-06-23",{"date":101,"type":39},"2026-06-24",{"date":103,"type":39},"2026-01-21",{"date":105,"type":22},"2026-08",{"name":45,"class":46},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":56,"sex":17,"minAge":115,"maxAge":57,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":47},"100372844","acupuncture-for-pain-control-after-ambulatory-knee-arthroscopy-100372844","NCT04134702","Acupuncture for Pain Control After Ambulatory Knee Arthroscopy","Acupuncture vs. Standard Therapy for Treatment of Postoperative Pain in Patients Scheduled for Arthroscopic Knee Surgery - a Pilot Non-randomized Controlled Trial","AcuK-Scope","Inclusion Criteria:\n\n1. Patients with an American Society of Anesthesiologists physical status of I to II scheduled for elective ambulatory arthroscopic knee surgery under standardized general anesthesia\n2. Surgery time does not exceed 80 minutes\n3. Patients without previous opioid and psychotropic medication\n4. Patients aged between 19 and 55 years, able to fill in the study questionnaire (Appendix F)\n5. Patients who have given written informed consent\n\nExclusion Criteria:\n\n1. Current psychiatric disease\n2. Local skin infection at the sites of acupuncture\n3. Aged \\\u003C 19 or \\> 55 years\n4. Failure to follow the standardized schema of general anaesthesia\n5. Surgery time more than 80 minutes\n6. Intraoperative complications (bleeding, required blood transfusion more than 6 units of packed cells, cardiovascular instability, required catecholamines)\n7. Patients who consumed opioid medication at least 6 months before surgery\n8. Patients who are unable to understand the consent form or to fill in the study questionnaire.","19 Years",{"count":117,"type":22},60,[25],"Aim of the study: To investigate whether acupuncture with indwelling fixed needles reduces pain and analgesic requirement and foster mobilization in patients after arthroscopic knee surgery (AKS) Design: Prospective pilot investigation with non-randomized arm Number of patients: N = 60 (30 patients with acupuncture additional to standard pain treatment (SPT) vs. 30 patients with SPT only Inclusion criteria: Adult patients scheduled to elective AKS in general anaesthesia with \\\u003C 80 min. duration Without previous opioid and psychotropic medication Given informed consentOutcome measures: Postoperative analgesic requirement; Pain intensity; Incidence of side effects; Physiological parameters; Mobilization score",[121],"Postoperative Pain; Knee Arthroscopy; Acupuncture","2026-06-08",{"date":124,"type":39},"2026-06-09",{"date":126,"type":39},"2019-02-01",{"date":128,"type":22},"2027-12-31",{"name":45,"class":46},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":150,"locationsCount":47},"100577290","a-comparison-of-fisetin-kinetics-in-young-and-old-adults-100577290","NCT06796374","A Comparison of Fisetin Kinetics in Young and Old Adults","A Comparison of Fisetin Kinetics in Young and Old Adults - FISEKIN-1","FISEKIN-1","Inclusion Criteria:\n\n* any sex\n* age between 18 and 30 years or ≥ 65 years\n* understands the study purpose and design\n* contractually capable and provides signed informed consent form\n* healthy condition or mild and\u002For well-treated forms of allergies, asthma, hypertension, and orthopedic diseases\n* a maximum of 3 chronically taken drugs\n\nExclusion Criteria:\n\n* BMI \\> 30 kg\u002Fm2 and \\\u003C 18 kg\u002Fm2\n* body weight \\\u003C 48 kg\n* women in young cohort: known pregnancy or lactation period; positive urine pregnancy test at screening or kinetic visit\n* men: hemoglobin \\\u003C 8,3 mmol\u002Fl women: hemoglobin \\\u003C 7,3 mmol\u002Fl\n* elevated liver function tests (1 or more of ALAT, ASAT, yGT, Bilirubin \\> 2x ULN)\n* reduced renal function (eGFRMDRD \\\u003C 60 ml\u002Fmin\u002F1,7 m2)\n* QTcF \\> 450 ms in screening ECG\n* psychiatric disease requiring recent or actual treatment\n* drug dependency at the time of visit\n* use of recreational drugs more than twice a week\n* any known hypersensitivity or allergic reactions to fisetin\n* history of severe hypersensitivity reactions and\u002For anaphylaxis\n* poor venous conditions that make it impossible to place a peripheral venous catheter and regularly draw blood through it\n* intake of drugs undergoing extensive metabolism via CYP1A2, CYP2D6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and\u002For Pgp and with narrow (monitoring-requiring) therapeutic range during the past seven days if the duration of intake was at least two days\n* intake of COMT-inhibitors during the past seven days if the duration of intake was at least two days\n* intake of drugs or dietary supplements containing fisetin within the two days before or during the kinetic visits\n* individuals who have eaten food with high fisetin content in the two days before the kinetic visits (e.g. strawberry, apple, persimmon, grape, mango, kiwi, peach, tomato, onion, lotus roots, kale, cucumber; processed products, e.g. wine)",{"count":139,"type":22},80,[25],"This study investigates the differences in the kinetic parameters of fisetin in two cohorts of healthy volunteers:\n\nCohort 1) volunteers aged 18-30 years (n = 40) Cohort 2) volunteers aged 65 years or older (n = 40)\n\nThe purpose of this study is:\n\n1. To describe the fisetin kinetics after a single dose oral administration in older age.\n2. To compare the fisetin kinetics after a single dose oral administration in old and young age.\n\nFISEKIN-1 is designed as a four-arm study protocol. As well as two different age groups (18-30 years vs. 65 years and older), we want to compare fisetin kinetic parameters in fasted and fed condition:\n\nArm 1) 500 mg fisetin (1x 5 capsule), fasted condition, cohort 1: young age Arm 2) 500 mg fisetin (1x 5 capsule), fasted condition, cohort 2: old age Arm 3) 500 mg fisetin (1x 5 capsule), fed condition, cohort 1: young age Arm 4) 500 mg fisetin (1x 5 capsule), fed condition, cohort 2: old age",[143],"Pharmacokinetic Study in Healthy Volunteers","2026-03-31",{"date":146,"type":39},"2026-04-06",{"date":144,"type":22},{"date":149,"type":22},"2027-07-31",{"name":45,"class":46},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":56,"sex":17,"minAge":159,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":162,"phases":4,"briefSummary":163,"conditions":164,"keywords":168,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":47},"100593711","coronary-and-cerebral-microvascular-dysfunction-in-neurological-diseases-100593711","NCT07009990","Coronary and Cerebral Microvascular Dysfunction in Neurological Diseases","The Greifswald Heart and Brain Project: Coronary and Cerebral Microvascular Dysfunction in Patients With Acute Neurological Diseases","G-HeBra","Inclusion Criteria:\n\n* Men and women, minimum age: 45 years\n* Gave informed consent\n* Specifically for patient group: Admission to hospital due to an acute neurological event due to acute first-time stroke (ischemic or hemorrhage; mild to moderate in severity based on The National Institutes of Health Stroke Scale \\[NIHSS\\], score \\\u003C15) and able to provide informed consent (e.g., no or only mild aphasia; no impairment of consciousness), first-time generalized epileptic seizure (with focal or generalized onset), or transient global amnesia\n\nExclusion Criteria:\n\n* History of stroke or any type of seizure\n* Neurodegenerative neurological disorders including dementia, Parkinson's disease, Huntington's disease, and Amyotrophic lateral sclerosis\n* Acute myocardial infarction requiring revascularization\n* Severe and untreated medical conditions, including advanced-stage malignant tumors and cardiac diseases resulting in cardiogenic shock or acute heart failure\n* Severe infections (C-Reactive Protein \\[CRP\\] \\> 50 mg\u002FdL)\n* History of severe alcoholism or use of drugs\n* Severe psychiatric disorders such as moderate to severe depression (if not in remission) or psychosis\n* Contraindication to magnetic resonance imaging or renal dysfunction with eGFR (estimated glomerular filtration rate) \\\u003C 30 ml\u002Fmin\u002F1.73 m2, which would not allow the administration of the contrast agent gadolinium","45 Years",{"count":161,"type":22},100,"OBSERVATIONAL","Neurological and cardiovascular diseases are increasing in relative and absolute terms globally, and pose a major burden in terms of morbidity, mortality, quality of life and healthcare costs. Increasing evidence has been found that disorders of blood circulation in the smallest vessels of the heart and the brain share similar risk factors as well as mechanisms but evidence about the potential link between both remains scarce.\n\nTherefore, this study wants to investigate whether in patients with acute first-time stroke, first-time generalized epileptic seizure or first-time transient global amnesia, impairment in microcirculation is found in the brain and in the heart within 72 hours after the onset of first symptoms. We also intend to examine differences in structural brain as well as cardiac health parameters and in blood biomarkers between patients with acute neurological diseases and healthy controls matched for age, sex and major cardiovascular risk factors like diabetes, smoking and high blood pressure. In addition, we will characterize the cohorts in terms of cognitive function and questionnaires on lifestyle and self-reported emotional functioning. We expect lower circulation in the smallest blood vessels in the brain and in the heart in patients with acute neurological diseases compared to healthy controls.\n\nThis pilot project is intended to demonstrate feasibility and initial results and thus serve as the basis for a larger clinical trial to improve long-term cerebral and cardiac health in patients with acute neurological diseases",[165,166,167],"Stroke","Epilepsy","Transient Global Amnesia (TGA)",[169,170,171,172,173,174,175,176,177,178,179,180,181],"neurological diseases","cardiovascular health","perfusion","microvascular dysfunction","magnetic resonance imaging","transthoracic echocardiogram","cognitive function","stroke","transient global amnesia","epilepsy","brain health","microcirculation","Takotsubo syndrome","NOT_YET_RECRUITING","2025-06-03",{"date":185,"type":39},"2025-06-08",{"date":187,"type":22},"2025-06",{"date":189,"type":22},"2027-06",{"name":45,"class":46},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":199,"minAge":18,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":47},"100425256","cognitive-training-and-brain-stimulation-in-women-with-post-chemotherapy-cognitive-impairment-100425256","NCT04817566","Cognitive Training and Brain Stimulation in Women With Post-chemotherapy Cognitive Impairment","Neuromodulation Through Brain Stimulation-assisted Cognitive Training in Patients With Post-chemotherapy Cognitive Impairment","NeuroMod-PCCI","Inclusion Criteria:\n\n1. Chemotherapy to treat breast cancer (≥ 6 months post-treatment).\n2. Self-reported concerns regarding cognitive functioning.\n3. Age: 18-65 years.\n4. right-handedness\n\nExclusion Criteria:\n\n1. History of dementia before treatment of cancer.\n2. Other neurodegenerative neurological disorders; epilepsy or history of seizures.\n3. Severe and untreated medical conditions that preclude participation in the training, as determined by responsible physician.\n4. History of moderate to severe substance use disorder according to DSM-5\n5. Moderate to severe acute psychiatric disorders according to DSM-5\n6. Contraindication to tDCS application (Antal et al., 2017)","FEMALE","65 Years",{"count":202,"type":22},52,[25],"The aim of this study is to investigate whether a high definition tDCS-accompanied intensive cognitive training of working memory leads to performance improvement in women with post-chemotherapy cognitive impairment after breast cancer treatment.",[206,207],"Breast Cancer","Cognitive Impairment","2025-04-01",{"date":210,"type":39},"2025-04-04",{"date":212,"type":39},"2021-11-02",{"date":214,"type":22},"2026-06",{"name":45,"class":46},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":162,"phases":4,"briefSummary":225,"conditions":226,"keywords":230,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":47},"100477777","comparison-of-the-physical-activity-in-cancer-patients-assessed-by-questionnaire-and-motion-tracker-100477777","NCT05501379","Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker","Comparison of the Physical Activity Assessed by an Accelerometer and the International Physical Activity Questionnaire in Oncologic Patients","OncoPhys","Inclusion Criteria:\n\n* verified diagnosis of lymphoma, colorectal or pancreatic cancer\n* requirement of surgical, chemo or radio therapy\n* provision of informed consent\n\nExclusion Criteria:\n\n* pregnancy\n* inability to provide consent\n* use of a rollator",{"count":117,"type":22},"Physical activity is an important aspect of cancer therapy but correct measurement of physical activity is difficult. In this study, the physical activity of patients undergoing cancer therapy is assessed by questionnaire and by motion tracker. The results are then compared to answer whether there are differences between the two measurements. Findings of this study will help to improve the assessment of physical activity in cancer patients.",[227,228,229],"Lymphoma","Pancreas Cancer","Colorectal Cancer",[231,232,233,234,235,236,237],"Physical Activity","Accelerometer","International Physical Activity Questionnaire","Cancer Therapy","GeneActiv","Quality of Life","Fatigue","2024-12-23",{"date":240,"type":39},"2024-12-27",{"date":242,"type":39},"2022-09-21",{"date":244,"type":22},"2025-03-31",{"name":45,"class":46},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":253,"targetDuration":18,"studyType":162,"phases":4,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},"100434623","european-disease-registry-on-retinopathy-of-prematurity-rop-100434623","NCT04939571","European Disease Registry on Retinopathy of Prematurity (ROP)","EU-ROP","Inclusion Criteria:\n\n* ROP requiring treatment according to the respective national ROP screening and treatment guidelines\n\nExclusion Criteria:\n\n* Denial or absence of consent for documentation and electronic storage of personal data by parents or legal guardians",{"count":254,"type":22},3000,"The EU-ROP registry is a European wide multicenter non-interventional observational registry study intended to run open-ended in as many countries as possible including infants treated for retinopathy of prematurity irrespective of the used treatment modality. The registry is strictly observational; only clinical routine data is collected, no study-specific examinations or interventions are to be performed.\n\nThe aim of the EU-ROP registry is to collect information on as many patients as possible treated for ROP in Europe. Both the number of study centers as well as the number of patients to be included into the registry are not limited.\n\nThe primary objective is to describe the typical clinical features of infants with severe ROP, variations in phenotype, and the clinical progression of the disease over time (natural history) in different European countries as well as to study treatment patterns, follow-up patterns, as well as long-term outcomes.",[257],"Retinopathy of Prematurity",[259,260,261,262,263],"ROP","anti-VEGF","laser coagulation","epidemiology","non-interventional study","2024-01-22",{"date":266,"type":39},"2024-01-24",{"date":268,"type":39},"2021-08-06",{"date":270,"type":22},"2039-08",{"name":45,"class":46},59,{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":56,"sex":17,"minAge":200,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100513187","ship-age-frailty-renal-function-and-multi-component-primary-care-in-rural-mecklenburg-western-pomerania-100513187","NCT05962203","SHIP-AGE: Frailty, Renal Function, and Multi-component Primary Care in Rural Mecklenburg-Western Pomerania","SHIP-AGE: Frailty, Renal Function, and Multi-component Primary Care in Rural Mecklenburg-Western Pomerania.","MV-FIT","Inclusion Criteria:\n\n* age 65 years or older\n* mGFR \\> 30 mL\u002Fmin per 1.73 m2\n* being able to understand and give written informed consent.\n\nExclusion Criteria:\n\n* bedridden\n* palliative\n* inability to consent\n* severe dementia\n* inability to speak\n* lack of compliance (paracusis, inability to fulfill at least 60% of the assessments)","100 Years",{"count":283,"type":22},820,[25],"Chronic kidney disease (CKD) is a leading risk factor for cardiovascular and all-cause mortality among the elderly. Mecklenburg-Western Pomerania has the largest prevalence of CKD in Germany and Europe. The CKD impact in primary care strategies to reduce frailty syndrome in the elderly is unknown. For this purpose, about 820 elderly participants will be included in an observational study (MV-FIT), who will undergo an multi-factorial geriatric assessment, monitoring \\& management program, specifically designed to avoid frailty. The goal of the full-scale study is to evaluate the impact of CKD in multi-component primary care strategies to reduce frailty among elderly persons in rural Mecklenburg-Western Pomerania. MV-FIT will be conducted on individuals in rural Mecklenburg-Western Pomerania, who will be observed over a period of 3 years. The Study of Health in Pomerania (SHIP) is a population-based epidemiological, two independent-cohort, study (SHIP and SHIP-TREND). SHIP cohorts have been followed for \\>24 years. SHIP\u002FSHIP TEND participants \\>60 years or older will studied by a follow-up survey. The aim is to gain new insights into the development of frailty and to develop strategies for keeping those affected healthy.",[287],"Frailty Syndrome",[289,290,291,292,293,294],"Chronic kidney disease","Frailty","Falls","Cognitive decline","Multi-component interventions","Rural communities","2023-07-18",{"date":297,"type":39},"2023-07-27",{"date":299,"type":22},"2023-09-01",{"date":301,"type":22},"2029-12-31",{"name":45,"class":46},""]